GlassScriptPhysician profile
Fadi Haddad
NPI 1487322681
$18,562.48
in general payments reported to CMS, 2019-2025
19 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $598 · 2023: $889 · 2024: $342 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Food and Beverage: $1,560 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Travel and Lodging: $47.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,356.50 |
| Food and Beverage | $1,560.11 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Travel and Lodging | $47.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,772.34 | 2023-2025 | Calquence |
| Glaxosmithkline, LLC. | $3,672.88 | 2025 | Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $3,187.50 | 2025 | |
| Eli Lilly and Company | $1,562.50 | 2025 | |
| Lilly USA, LLC | $1,283.49 | 2024-2025 | Jaypirca, Verzenio |
| Adaptive Biotechnologies Corporation | $789.04 | 2022-2025 | Clonoseq |
| Daiichi Sankyo INC. | $650.00 | 2025 | Vanflyta |
| Astellas Pharma US INC | $401.40 | 2022-2024 | Xospata |
| Amgen INC. | $341.50 | 2025 | Blincyto |
| Abbvie INC. | $210.10 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $150.00 | 2023 | Opdivo |
| Novartis Pharmaceuticals Corporation | $149.61 | 2023-2025 | |
| Beone Medicines USA, INC. | $142.89 | 2025 | Brukinsa |
| Astellas Pharma Global Development | $66.38 | 2022 | |
| Celgene Corporation | $58.92 | 2023-2024 | Reblozyl |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $48.16 | 2024 | Jakafi |
| Jazz Pharmaceuticals INC. | $29.82 | 2023 | |
| Medtronic, INC. | $23.83 | 2023 | Emprint |
| Aimmune Therapeutics, INC. | $22.12 | 2025 | Vowst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadi Haddad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.